Zydus to buy Assertio for $166.4 million

Zydus is acquiring US-based Assertio Holdings for $166.40 million to bolster its specialty oncology presence in the US. The deal, structured as a tender offer followed by a merger, will give Zydus access to Assertio's commercial platform and its approved oncology asset, Rolvedon. This strategic move aims to expand Zydus's footprint in the US specialty oncology market.